New combo therapy may open door to liver transplant for advanced bile duct cancer patients

NCT ID NCT07471165

First seen Mar 17, 2026 · Last updated May 15, 2026 · Updated 8 times

Summary

This study tests whether giving a PD-L1 antibody (a type of immunotherapy) together with chemotherapy and radiation can shrink advanced bile duct cancer enough to allow patients to receive a liver transplant. The trial will enroll 25 adults aged 18-70 with locally advanced perihilar cholangiocarcinoma that cannot be surgically removed. The main goal is to see how many patients can successfully undergo a liver transplant after this pre-treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PERIHILAR CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jinling Hospital of Nanjing University

    Nanjing, Jiangsu, 210000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210002, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.